NeOnc Technologies Holdings, Inc. (NTHI): Major Insider Purchases, 2025 Financial Results, and Multiple Near-Term Catalysts

Key Highlights

• Significant insider purchase: Chairman and CEO Amir Heshmatpour buys ~\$300,000 of NTHI stock, signaling management’s strong confidence in the company’s undervalued shares ahead of key catalysts.
• Upcoming clinical and regulatory milestones:
  • NEO100: Interim data readout expected in approximately 4 months (around August 2026).
  • NEO212: Type B End-of-Phase FDA meeting in the next 4 weeks to discuss a potential pivotal, registrational Phase 2 study. Exploring Accelerated Approval pathway.
• 2025 financial results explained:
  • Reported net loss of ~\$62 million for 2025, but ~73% of this is due to non-cash stock-based compensation and one-time listing-related advisory fees.
  • Normalized ongoing cash operating expenses are ~\$10.1 million for the year.
• Balance sheet improvement:
  • Raised ~\$13 million in private placement financing in Q1 2026, used to repay outstanding short-term convertible debt and meet accrued obligations, strengthening the company’s financial position.

Detailed Report

Insider Buying Activity

NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biopharmaceutical company focused on central nervous system (CNS) cancers, announced that its Chairman and CEO, Amir Heshmatpour, purchased approximately \$300,000 worth of company stock in the past week. This move is a clear signal to the market of management’s conviction that NTHI shares are undervalued, especially as the company approaches several critical value-driving events. Insider buying of this magnitude is typically viewed as a bullish indicator and may have a positive impact on investor sentiment and share price.

Key Near-Term Catalysts

• NEO100: The company anticipates an interim data readout for its NEO100 program in about four months. NEO100 is being investigated in a Phase 2a trial for IDH1-mutant recurrent high-grade glioma, a form of brain cancer with limited treatment options. The data readout, expected around August 2026, is a key inflection point for the company and could significantly influence share price depending on the results.
• NEO212: NEO212 has completed Phase 1, with the recommended Phase 2 dose (RP2D) set at 610 mg. Early data suggests possible clinical efficacy, including potentially durable disease control in heavily pretreated recurrent glioblastoma (GBM) and brain metastasis patients. The company will hold a crucial Type B End-of-Phase FDA meeting within the next four weeks to align on the design of a pivotal, registrational Phase 2 study. NTHI is also exploring an Accelerated Approval pathway for NEO212, which, if successful, could expedite commercialization and market access.

2025 Financial Results and Context

For the fiscal year ending December 31, 2025, NTHI reported a net loss of approximately \$62 million. However, it is critical for investors to note that roughly 73% of this loss (about \$45.2 million) is attributable to non-cash stock-based compensation (\$35.6 million) and one-time listing-related advisory fees (\$9.6 million). These items significantly inflate the reported loss but do not reflect the ongoing cash burn or core operating expenses.

The stock-based compensation relates to the 2023 Equity Plan, covering a three-year period and including awards to employees, executives, and key contributors. The one-time advisory fees were linked to the company’s public listing and are not expected to recur. After adjusting for these items (and a \$0.7 million litigation settlement), the normalized ongoing cash operating expenses for 2025 were about \$10.1 million.

This normalization provides a clearer view of the company’s underlying cost structure and capital efficiency going forward.

Strengthened Financial Position

In the first quarter of 2026, NTHI successfully raised gross proceeds of approximately \$13.0 million in a private placement financing. These funds were used in part to pay down outstanding short-term convertible debt and satisfy certain accrued obligations, thereby strengthening the company’s balance sheet. Management emphasized that this improved liquidity, combined with disciplined expense management, positions NTHI to advance its key clinical programs and milestones.

Clinical Program Updates and Potential Price Catalysts

• NEO212:
  • Phase 1 complete, RP2D set at 610 mg.
  • Early efficacy signals in recurrent GBM and brain metastases, even in a heavily pretreated population.
  • Type B FDA meeting within 4 weeks to discuss pivotal Phase 2 study design.
  • Potential for Accelerated Approval pathway, which could provide earlier-than-expected market entry.
  • First oral bio-conjugated temozolomide asset, potentially overcoming known resistance mechanisms (MGMT-mediated TMZ resistance).
• NEO100:
  • Phase 2a fully enrolled for IDH1-mutant high-grade glioma; interim data readout expected August 2026.
  • Recent data (from expanded cohort and compassionate use) showed:
    • 24% radiographic remission rate (6 of 25 patients), compared to ~8% seen historically with salvage therapies.
    • 44% six-month progression-free survival (historical benchmarks: 21–31%).
    • 36% of patients alive ≥18 months post-treatment initiation.
    • No significant toxicity, even with prolonged dosing.
  • AI-driven findings suggest that ultrasound may enhance NEO100’s potency against primary and metastatic brain tumors, indicating potential for combination approaches.

Business Overview

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing CNS therapeutics that cross the blood-brain barrier. Its NEO™ drug development platform covers a portfolio of novel drug candidates and delivery methods, with patent protection through 2038. Both NEO100™ and NEO212™ are in Phase II human clinical trials and are advancing under FDA Fast-Track and IND status. The company licenses its intellectual property portfolio from the University of Southern California.

Key Considerations for Shareholders

• Insider buying by the CEO is a strong vote of confidence and may be perceived as a bullish signal by the market.
• Multiple near-term data and regulatory catalysts could significantly impact the share price—positive clinical data or regulatory alignment for NEO100 or NEO212 could drive substantial re-rating.
• The company has addressed liquidity concerns with a recent private placement and deleveraging actions.
• Investors should remain mindful of the non-recurring nature of large reported losses and focus on normalized cash operating expenses and clinical progress.
• Risks remain, including clinical trial outcomes, regulatory approvals, and the need for further funding to advance programs through pivotal studies and toward commercialization.

Contact and Further Information

• Company Contact: [email protected]
• Investor Relations: James Carbonara, Hayden IR, (646)-755-7412, [email protected]
• Website: https://neonc.com

Disclaimer: This article contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially due to various factors, including but not limited to clinical trial outcomes, regulatory decisions, and market conditions. Readers are encouraged to review the company’s filings with the Securities and Exchange Commission for more information on risk factors. This article does not constitute investment advice. Always conduct your own research or consult a financial advisor before making investment decisions.

View NEONC TECHNOLOGIES HOLDINGS, INC. Historical chart here